在SunRISe-2试验中,研究人员比较了TAR-200联合cetrelimab与传统化疗的效果。 SunRISe-2是一项3期、随机、对照、多中心的国际试验,专门针对那些不适合或不愿接受膀胱全切除术的肌肉浸润性膀胱癌患者,评估TAR-200联合cetrelimab与传统治疗的...
New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer. Retrieved January 15, 2025. ...
对于MIBC,正在进行SunRISe-2和SunRISe-4两项研究。 TAR-200研究的未来似乎看起来充满希望。 #膀胱癌#$强生(JNJ)$ 参考资料: 1.Balar, Arjun V et al. “Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, si...
1. Johnson & Johnson’s investigational TAR-200 granted US FDA breakthrough therapy designation for the treatment of high-risk non-muscle-invasive bladder cancer. News release. Johnson & Johnson. December 4, 2023. Accessed January 5, 2024. 2. Necchi A, Jacob JM, Daneshmand S, et al. LBA...
FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer. News Release. Johnson & Johnson.’香港登越药业温馨提示:本文旨在介绍医药健康研究,不作任何用药依据,具体用药指引,请咨询主治医师。 送TA礼物 1楼...
Efficacy of TAR-200 in Patients With Muscle-invasive Bladder CancerTyson, Mark D.Morris, DavidPalou, JuanRodriguez, OscarCarmen Mir, MariaDickstein, Rian J.Guerrero-Ramos, FélixScarpato, Kristen R.Hafron, Jason M.Messing, Edward M.AUANews...
310 Bladder Cancer Genitourinary Oncology Donald Lamm 美国 Arizona Phoenix 311 Winthrop University Hospital Anthony Corcoran 美国 New York Mineola 312 Carolina Urologic Research Center Neal Shore 美国 South Carolina Myrtle Beach 313 Stephenson Cancer Center Sanjay Patel 美国 Oklahoma Oklahoma City 314 Winshi...
Michiel S.Van der Heijden,et al.TAR-200+/-cetrelimab(CET)and CET alone in patients(pts)with bacillus Calmette-Guérin-unresponsive(BCG UR)high-risk non-muscle-invasive bladder cancer(HR NMIBC):Updated results from SunRISe-1(SR-1).ESMO2024.LBA 85. ...
Johnson & Johnson has kicked off a marketing application in the US for TAR-200 as a treatment for a form of bladder cancer, using a novel technology that releases the drug intravesically, or directly...查看全文 相关企业信息 公司名称:强生(中国)有限公司 法人代表:ARPAPORN SAMABHANDHU 注册资本...
2407TiP SunRISe-3: TAR-200 plus cetrelimab (CET) or TAR-200 versus intravesical bacillus Calmette-Guérin (BCG) in patients (pts) with BCG-naive high-risk non-muscle-invasive bladder cancer (HR NMIBC) Author links open overlay panelA. Necchi 1, J.W.F. Catto 2, T.B. Powles 3, F...